Further to the "Supraphysiological Androgens [SPA] Promote Tumor Suppressive Activity of the AR Through cMYC Repression and Recruitment of the DREAM Complex" thread, here's a handful of papers of interest.
However, amongst all the US Food and Drug Administration (FDA)-approved targeted therapies for MYC-dependent cancers, the only inhibitors that exploit vulnerabilities of MYC, are those of mTOR (everolimus, sirolimus, and tesirolimus) and of IMPDH (mycophenolic acid)
I take 2 mg of sirolimus once weekly. I am going to up that to 5 mg during high T and leave at 2 mg during low T.
Seems an immunosupressant like sirolimus could do more harm than good, particularly for those of us trying to encourage our immune systems to fight PCa (layman's view)?
High dose = immunosuppressive. Low dose = immuno supportive. FDA approved c-Myc inhibitor and mTOR inhibitor. "On November 22, 2021, the FDA approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (brand name Fyarro) for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor."
I don't use the suspension. I toggle between 2 and 5 mg once weekly. PSA seems to react. However, I use it as part of a BAT regimen.
Some people use it stand-alone. I don't know how effective it is stand-alone. Also, it inhibits anabolism on the day it is used. But it increases fat reduction. Some bodybuilders use it for that purpose.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.